Epstein‑Barr virus‑associated primary central nervous system lymphoma in an immunosuppressed patient with a comorbid autoimmune disorder: A case report
- Authors:
- Published online on: July 10, 2023 https://doi.org/10.3892/etm.2023.12109
- Article Number: 410
-
Copyright: © Bricoune et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Patients with primary central nervous system lymphoma (PCNSL) typically present with non‑focal neurological symptoms, including disorientation, poor balance and memory loss with unifocal or multifocal periventricular lesions seen on MRI. Deviations from these characteristic findings can delay diagnosis and lead to additional diagnostic tests being needed. The present study reports a 68‑year‑old man with a recent varicella zoster infection and history of acetylcholine receptor antibody‑positive myasthenia gravis who received mycophenolate mofetil for 22 years. He presented with left eye vision changes and cognitive memory deficits. A brain MRI showed an enhancing lesion within his left medulla extending to the cerebellum. Cerebrospinal fluid analysis was positive for Epstein‑Barr virus (EBV) and negative for malignancy. He was diagnosed with varicella zoster virus vasculopathy. At 3 months later, a repeat brain MRI showed multiple new enhancing lesions developing bilaterally along the periventricular white matter. Soon after, he presented to a local ER with acute left‑sided blurry vision and worsening memory loss, and he began receiving steroids. Because of rapid symptom progression, he underwent resection of the left frontal lesion, which showed EBV‑induced diffuse large B‑cell lymphoma (DLBCL). Mycophenolate mofetil was discontinued, and within 24 h of one dose of intravenous 500 mg/m2 rituximab, he had a dramatic improvement in left eye vision and memory loss. He experienced mixed responses to rituximab after 3 cycles. Following one dose of high‑dose methotrexate, he developed subsequent chronic kidney disease and required dialysis. He received whole‑brain radiation therapy with craniospinal radiation and is currently in complete remission. An EBV‑induced DLBCL diagnosis should be highly considered for patients with periventricular lesions and EBV‑positive cerebrospinal fluid. Misdiagnosis or delay in PCNSL diagnosis because of atypical features in disease presentation and radiographic findings could lead to PCNSL progression and worsening neurological deficits.
